Clinical trials located in

Bardejov

Bardejov city is located in Slovakia. Currently, 14 clinical trials are being conducted in this city.

Bardejov, a UNESCO World Heritage Site in Slovakia, is renowned for its well-preserved medieval town center. Founded in the 13th century, this city boasts a unique collection of Gothic and Renaissance buildings, including the Basilica of St. Egidius with its 11 altars from the 15th century. The town hall, dating back to the 16th century, now houses the Šariš Museum, one of the oldest in Slovakia. Bardejov’s spa town, Bardejovské Kúpele, is famed for its healing waters and picturesque wooden churches, reflecting a rich history and cultural heritage.

  • CT-EU-00041455

    Study of the effectiveness of tanimilast in the treatment of pulmonary diseases

    A 52-week clinical trial is being conducted to investigate the effectiveness and safety of the new drug, known as Tanimilast (CHF6001), in people diagnosed with chronic bronchitis and chronic obstructive pulmonary disease (COPD). The primary aim of the study is to determine the effectiveness of CHF6001 administered as an addition to a standard COPD treatment regimen. Study participants will be randomly assigned to receive the study drug CHF6001 or a placebo, which will be taken concurrently with their existing COPD therapy. Key measurements in the study include monitoring the frequency and severity of COPD exacerbations, which are episodes of significantly worsening symptoms. Additionally, the study will assess changes in participants’ lung function and overall quality of life. Typically eligible for the study are adults who are 40 years of age or older, have a documented history of COPD and chronic bronchitis, and are current or former smokers. In particular, the study is of interest to people who have experienced at least one COPD exacerbation in the year preceding the study.

    AustriaBulgariaCzechiaGermanyGreeceHungaryNetherlandsPolandRomaniaSlovakiaSpainUnited Kingdom
  • Testing new medicine for resistant high blood pressure

    In this 20-week trial, the effectiveness, safety, and optimal dosage of a medication known as XXB750 are being evaluated in individuals with resistant high blood pressure (resistant hypertension). This condition persists despite the use of three different blood pressure medications. XXB750 will be administered through subcutaneous injections, and its efficacy will be compared to a placebo. A 2-week preparation period precedes the trial, during which participants receive three doses of the actual trial medicine and one dose as part of the preparation. Following the trial, participants will be monitored for an additional 8 weeks without receiving any trial medicine during this period. The primary focus is on assessing whether XXB750 can effectively reduce blood pressure when measured over a 24-hour period.

    AustriaBulgariaCzechiaFranceGermanyItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Evaluating epilepsy treatment with brivaracetam

    This study aims to see how effective and safe a drug called Brivaracetam is for children and young adults aged between 2 and 25 who have a type of epilepsy known as Absence Epilepsy. Brain activity will be recorded for 24 hours using a device on day 14. If the patient has not had an episode of epilepsy in the 4 days before the recording or during it, they are considered ‘free’ of seizures. If the patients experience a seizure, it will be recorded on the machine and these patients have to leave the study. These patients also should not be taking a type of drug known as benzodiazepine during the study. All people taking part will have to keep a diary of their seizures from the start of the study until the end.

    BelgiumItalyRomaniaSlovakiaSpain
  • Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Testing the effect and safety of tanimilast for COPD patients

    This study is a year-long experiment where the researchers will test the effectiveness and safety of two doses of a new drug called tanimilast. Tanimilast is added to the usual treatment for people with two lung conditions: COPD and Chronic Bronchitis. The drug will be tested and compared with a group that will take a placebo, a substance with no effect. The main aim is to see if tanimilast helps control the worsening of symptoms in COPD patients. These worsening instances are known as ‘exacerbations’ and can range in severity. Some might require extra medication.

    AlbaniaAustriaBulgariaCzechiaGermanyGreeceHungaryItalyNetherlandsPolandRomaniaSlovakiaSpainUnited Kingdom
  • Understanding new medicine in moderate to severe ulcerative colitis or Crohn’s disease

    This is a study about a medicine called TEV-48574, used to treat serious bowel diseases called ulcerative colitis and Crohn’s disease. The main purpose of this study is to see how well the medicine works and how much of it should be given to patients, specifically, every 4 weeks. The study aims to test two different doses of TEV-48574 while assessing its safety and the ease with which patients can manage it. Additionally, the research aims to analyze the long-term reactions of the body to the medication. Each participant will be observed for up to 66 weeks, and the entire study is expected to span approximately 37 months. The success of the treatment will be gauged through various tests, including the Mayo score, which considers symptoms such as rectal bleeding, stool frequency, and inflammation within the gut.

    AustriaBelgiumBulgariaCzechiaFranceHungaryItalyPolandSlovakiaSpain
  • Advancing asthma management: study evaluates triple therapy inhaler

    This Phase 3 study evaluates the PT010 inhaler, a combination of budesonide, glycopyrronium, and formoterol, in adults and adolescents with inadequately controlled asthma. The study compares PT010 to standard treatments, assessing its effectiveness in improving lung function and reducing asthma exacerbations. Approximately, 2200 participants will be enrolled and monitored over 24 to 52 weeks. The trial aims to improve asthma management and quality of life for those with persistent symptoms despite current treatments.

    CzechiaGermanyGreecePortugalSlovakiaUnited Kingdom
  • Long-term safety & effectiveness of rocatinlimab for atopic dermatitis

    This trial is all about studying a medicine called rocatinlimab for grown-ups and teens with a serious skin disease named atopic dermatitis (AD). The main goal is to see if rocatinlimab is safe and can help over a long period. The research will also check how well people tolerate the medication. The focus is on those who previously benefitted from the medicine, showing an improvement on a scoring system that measures itching levels. This trial falls in the third phase, making it crucial towards verifying the effectiveness and monitoring any adverse effects of the drug.

    AustriaCzechiaDenmarkFranceGermanyGreeceHungaryPolandPortugalSlovakiaSpain
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain
  • Comparison of milvexian and apixaban in reducing stroke risk in patients with atrial fibrillation

    This study is designed to compare two drugs, Milvexian and Apixaban to reduce the potential risk of stroke for patients suffering from atrial fibrillation, a common heart rhythm disorder. 15500 participants, aged 18 years and older will be invited to partake in this research. Participants will be randomly designated to receive either Milvexian or Apixaban. The study team aims to determine if Milvexian is at least as effective as Apixaban in reducing the risk of combined stroke and Non-central nervous system (CNS) systemic embolism. Furthermore, the research team will evaluate the occurrence rates of various health incidents including major bleeding, various cardiovascular complications, death, and other severe conditions over a 4-year period. The goal is to find out which medication proves safer and more effective in preventing severe health risks linked with this disorder. Study commencement is April 11, 2023, with completion targeted at May 5, 2027.

    BelgiumBulgariaCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom

See more clinical trials in other cities in Slovakia:

.